1. 首頁 > 健康養生 > >

深耕細作，以HER2為靶點的ADC藥物在晚期胃癌的廣泛探索( 四 )

健康知識養生常識


專家介紹
深耕細作，以HER2為靶點的ADC藥物在晚期胃癌的廣泛探索
文章圖片
黃鏡教授
中國醫學科學院腫瘤醫院內科副主任
醫學博士 ， 主任醫師 ， 教授 ， 美國NCI博士后 ， 博士生導師
中國臨床腫瘤學會(CSCO)理事
CSCO食管癌專家委員會副主任委員兼秘書長
北京腫瘤學會結直腸腫瘤專業委員會副主任委員
中國老年學和老年醫學會腫瘤康復分會副主任委員
CSCO腫瘤心臟病學專家委員會副主任委員
中國抗癌協會食管癌專業委員會常委
中國醫師協會結直腸腫瘤專業委員會常委
中國醫師協會結直腸腫瘤專業委員會內科治療委員會副主任委員
海峽兩岸醫藥衛生交流協會腫瘤防治專家委員會胃癌學組副組長
北京市希思科臨床腫瘤學研究基金會理事
參考文獻：
[1]SungH,FerlayJ,SiegelRL,etal.GlobalCancerStatistics2020:GLOBOCANEstimatesofIncidenceandMortalityWorldwidefor36Cancersin185Countries.CACancerJClin.2021May;71(3):209-249.
[2]BartleyAN,WashingtonMK,ColasaccoC,etal.HER2TestingandClinicalDecisionMakinginGastroesophagealAdenocarcinoma:GuidelineFromtheCollegeofAmericanPathologists,AmericanSocietyforClinicalPathology,andtheAmericanSocietyofClinicalOncology.JClinOncol.2017Feb;35(4):446-464.
[3]Bang,Y.J.;VanCutsem,E.;Feyereislova,A,etal.TrastuzumabincombinationwithchemotherapyversuschemotherapyalonefortreatmentofHER2-positiveadvancedgastricorgastro-oesophagealjunctioncancer(ToGA):aphase3,open-label,randomisedcontrolledtrial.Lancet(London,England)2010,376(9742),687-697.
[4]ChuaC,TanIB,YamadaY,etal.PhaseIIstudyoftrastuzumabincombinationwithS-1andcisplatininthefirst-linetreatmentofhumanepidermalgrowthfactorreceptorHER2-positiveadvancedgastriccancer.CancerChemotherPharmacol.2015Aug;76(2):397-408.
[5]JanjigianYY,KawazoeA,Ya?ezP,etal.TheKEYNOTE-811trialofdualPD-1andHER2blockadeinHER2-positivegastriccancer.Nature.2021Dec;600(7890):727-730.
[6]LiQ,JiangH,LiH,etal.EfficacyoftrastuzumabbeyondprogressioninHER2positiveadvancedgastriccancer:amulticenterprospectiveobservationalcohortstudy.Oncotarget.2016Aug2;7(31):50656-50665.
[7]HironakaS,UedaS,YasuiH,etal.Randomized,open-label,phaseIIIstudycomparingirinotecanwithpaclitaxelinpatientswithadvancedgastriccancerwithoutsevereperitonealmetastasisafterfailureofpriorcombinationchemotherapyusingfluoropyrimidineplusplatinum:WJOG4007trial.JClinOncol.2013Dec10;31(35):4438-4444.
[8]RAINBOW-Asia:Arandomized,multicenter,double-blind,phase3studyoframucirumabpluspaclitaxelversusplacebopluspaclitaxelinthetreatmentofadvancedgastricorgastroesophagealjunction(GEJ)adenocarcinomafollowingdiseaseprogressiononfirst-linechemotherapywithplatinumandfluoropyrimidine.2021ASCOGI.Abstract199.
[9]KangJH,LeeSI,LimDH,etal.Salvagechemotherapyforpretreatedgastriccancer:arandomizedphaseIIItrialcomparingchemotherapyplusbestsupportivecarewithbestsupportivecarealone.JClinOncol.2012May1;30(13):1513-1518.
[10]LiJ,QinS,XuJ,etal.Randomized,Double-Blind,Placebo-ControlledPhaseIIITrialofApatinibinPatientsWithChemotherapy-RefractoryAdvancedorMetastaticAdenocarcinomaoftheStomachorGastroesophagealJunction.JClinOncol.2016May1;34(13):1448-1454.
[11]KangYK,BokuN,SatohT,etal.Nivolumabinpatientswithadvancedgastricorgastro-oesophagealjunctioncancerrefractoryto,orintolerantof,atleasttwopreviouschemotherapyregimens(ONO-4538-12,ATTRACTION-2):arandomised,double-blind,placebo-controlled,phase3trial.Lancet.2017Dec2;390(10111):2461-2471.
[12]TsuchikamaK,AnZ.Antibody-drugconjugates:recentadvancesinconjugationandlinkerchemistries.ProteinCell.2018Jan;9(1):33-46.
[13]JinY,SchladetschMA,HuangX,etal.Steppingforwardinantibody-drugconjugatedevelopment.PharmacolTher.2022Jan;229:107917.
[14]NakadaT,SugiharaK,JikohT,etal.TheLatestResearchandDevelopmentintotheAntibody-DrugConjugate,[fam-]TrastuzumabDeruxtecan(DS-8201a),forHER2CancerTherapy.ChemPharmBull(Tokyo).2019;67(3):173-185.